Literature DB >> 15705916

KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.

Elena Tamborini, Elisa Gabanti, M Stefania Lagonigro, Tiziana Negri, Silvana Pilotti, Marco A Pierotti, Sabrina Pricl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15705916

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  11 in total

Review 1.  An update on molecular genetics of gastrointestinal stromal tumours.

Authors:  L Tornillo; L M Terracciano
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

2.  Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

Authors:  Alessandro Gronchi; Marco Fiore; Francesca Miselli; Maria Stefania Lagonigro; Paola Coco; Antonella Messina; Silvana Pilotti; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

3.  Current clinical strategy for imatinib-resistant gastrointestinal stromal tumors.

Authors:  Masayoshi Yamamoto; Hiroyuki Konno
Journal:  Clin J Gastroenterol       Date:  2009-04-18

4.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

5.  Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.

Authors:  Salah-Eddin Al-Batran; Joerg Thomas Hartmann; Florian Heidel; Jan Stoehlmacher; Eva Wardelmann; Claudius Dechow; Markus Düx; Jacob Robert Izbicki; Thomas Kraus; Thomas Fischer; Elke Jäger
Journal:  Gastric Cancer       Date:  2007-09-26       Impact factor: 7.370

6.  Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Authors:  Ken-Hong Lim; Ming-Jer Huang; Li-Tzong Chen; Tsang-En Wang; Chien-Liang Liu; Cheng-Shyong Chang; Mei-Chin Liu; Reuy-Kuen Hsieh; Chin-Yuan Tzen
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

7.  Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Authors:  Scott E Woodman; Jonathan C Trent; Katherine Stemke-Hale; Alexander J Lazar; Sabrina Pricl; Giovanni M Pavan; Maurizio Fermeglia; Y N Vashisht Gopal; Dan Yang; Donald A Podoloff; Doina Ivan; Kevin B Kim; Nicholas Papadopoulos; Patrick Hwu; Gordon B Mills; Michael A Davies
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

8.  The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Authors:  Tzu-Yin Lin; Misty Bear; Zhenjian Du; Kevin P Foley; Weiwen Ying; James Barsoum; Cheryl London
Journal:  Exp Hematol       Date:  2008-07-26       Impact factor: 3.084

Review 9.  Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.

Authors:  Philippe A Cassier; Armelle Dufresne; Samia Arifi; Hiba El Sayadi; Isabelle Ray-Coquard; Pierre-Paul Bringuier; Jean-Yves Scoazec; Laurent Alberti; Jean-Yves Blay
Journal:  Curr Gastroenterol Rep       Date:  2008-12

Review 10.  The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.

Authors:  Alessandra Maleddu; Maria A Pantaleo; Margherita Nannini; Guido Biasco
Journal:  J Transl Med       Date:  2011-05-23       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.